Prescribes the safety standards applicable to incomplete vehicles to the extent that the standard governs the components fitted on the incomplete vehicle. The Department believes it is necessary to prescribe the safety standards that are applicable to incomplete vehicles. Furthermore, this paragraph is in harmony with subparagraph 567.5 b ; 1 ; of the proposed U.S standard. The CVMA also requested that the Department eliminate the requirement for the NSM to appear on the information label. This request was not granted because the NSM clearly establishes the obligations of each manufacturer under the Motor Vehicle Safety Act and provides the Department with the authority to audit manufacturers of incomplete vehicles. Finally, like the TMA, the CVMA requested the elimination of the requirement for the GVWR and GAWRs to be indicated on information labels, a request that was rejected for the reasons already stated. In October 2001, the Department held one final round of consultations. Comments were received from the CVMA, which reiterated its requests of June 2001 and requested that the effective date of the amendment be made one year after its publication in the Canada Gazette, Part II. The Department granted the latter request. In preparing this amendment, the Department of Transport has made every reasonable effort to respond to the concerns and suggestions of the incomplete vehicle industry, without reducing the safety of vehicles. The Department believes that, by instituting a logical and transparent series of steps that clearly lays out the duties and responsibilities of each manufacturer involved, this amendment will improve the safety of vehicles manufactured in two or more stages. Compliance and Enforcement Motor vehicle manufacturers and importers are responsible for ensuring that their products comply with the requirements of the Motor Vehicle Safety Regulations. The Department of Transport monitors the self-certification programs of manufacturers and importers, including incomplete vehicle manufacturers, intermediate manufacturers, and final-stage manufacturers, by reviewing their test documentation, inspecting vehicles, and testing vehicles obtained in the open market. When a defect is found, the manufacturer or importer must issue a notice of defect to owners and to the Minister of Transport. If a vehicle does not comply with a safety standard, the manufacturer or importer is subject to prosecution and, if found guilty, may be fined as prescribed in the Motor Vehicle Safety Act. Contact Dan Davis Chief, Standards and Regulations Road Safety and Motor Vehicle Regulation Directorate Department of Transport 330 Sparks Street Place de Ville, Tower C Ottawa, Ontario K1A 0N5 Telephone: 613 ; 998-1956 FAX: 613 ; 990-2913 E-mail: davisda tc.gc.
HAMLIN ET AL. Hayes, E., Pugsley, M. K., Penz, W. P., Adaikan, G., and Walker, M. J. 1994 ; . Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. J. Pharmacol. Toxicol. Methods 32, 201207. Hey, J. A., del Prado, M., Sherwood, J., Kreutner, W., and Egan, R. W. 1996 ; . Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Drug Res. 46, 153158. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2002 ; . Draft Concensus Step 2 Guidelines. Safety pharmacology for assessing the potential for delayed ventricular repolarization QT interval prolongation ; by human pharmaceuticals. Khalifa, M., Drolet, B., Daleau, P., Lefez, C., Gilbert, M., Plante, S., O'Hara, G. E., Gleeton, O., Hamelin, B. A., and Turgeon, J. 1999 ; . Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J. Pharmacol. Exp. Ther. 288, 858 865. Kii, Y., Nakatsuji, K., Nose, I., Yabuuchi, M. Yasuyuki, Y., and Ito, T. 2001 ; . Effects of 5-HT 4 receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea pigs and conscious cats. Pharmacol. Toxicol. 89, 96 103. Levy, J. V. 1976 ; . Beta-adrenergic receptor blocking drugs in spontaneous hypertension. Am. J. Med. 61, 779 789. Meuldermans, W., Hendrickx, J., Lauwers, W., Hurkmans, R., Mostmans, E., Swysen, E., Bracke, J., Knaeps, A., and Heykants, J. 1998 ; . Excretion and biotransformation of cisapride in rats after oral administration. Drug Metab. Dispos. 16, 410 419. Roden, D. M., Bennett, P. B., Snyders, D. J., Balser, J. R., and Hondeghem, L. M. 1988 ; . Quinidine delays I k activation in guinea pigs ventricular myocytes. Circ. Res. 62, 10551058. Saitoh, M., Sugiyama, A., Nakazawa, T., and Hashimoto, K. 2002 ; . Cardiovascular effects of orally administered HNS-32, an originally synthesized anulene-1-carboxamidine derivative, assessed in the in vivo rat model. Jpn. J. Pharmacol. 89, 316 319. Shimizu, W., McMahon, B., and Antzelevitch, C. 1999 ; . Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsade de pointes in models of acquired and congenital long QT syndromes. J. Cardiovasc. Electrophysiol. 10, 156 164. Sun, Z. Q., Eddlestone, G. T., and Antzelevitch, C. 1997 ; . Ionic mechanisms underlying the effects of sodium pentobarbital to diminish transmural dispersion of repolarization. [abstr.] PACE 20, 111116. Van de Water, A., Verheyen, J., Xhonneux, R., and Reneman, R. S. 1989 ; . An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J. Pharmacol. Methods 22, 207217. Yaoita, H., Sakabe, A., Maehara, K., and Maruyama, Y. 2002 ; . Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 105, 975980.

In congestive heart failure patients with diabetes mellitus, worsening of hyperglycemia has occurred in 3 1% of carvedilol-treated patients and 2 6% of placebo-treated patients.
Some doctors were made in the name drug to require the 80-mg strength and clarinex.
2.1 Echocardiography assessment At 10 weeks after surgery, both LVMI and LVEDVI in banded group increased significantly over control group. In Catvedilol group, both LVMI and LVEDVI decreased significantly over banded group. This indicates that ventricular remodeling occurred in banded group animals, and Carvecilol could prevent this change effectively Table 1 ; . 2.2 Action potential AP ; APs were recorded in current-clamp mode and were elicited by 4 ms long rectangular pulses of depolarization current at basic cycle length BCL ; of 2 s , the current level was about 50% above threshold. At BCL of 2 s, AP duration measured at 90% depolarization, APD90 ; was prolonged significantly in myocytes from banded group compared with control group 664.746.2 ms, n 7 vs 522.019.5 ms, n 6, P 0.01 ; , and was shortened significantly in myocytes from Carved8lol group compared with banded group 567.814.3 ms, n 8 vs 664.746.2 ms, n 7, P 0.01 ; . 2.3 Na + Ca2 + exchanger current INa + Ca2 + ; INa + Ca2 + was recorded in voltage-clamp mode and mea. The great challenge faced by the pharmacogenomics industry at this point is the systematic correlation between normal versus disease patterns of gene expression in a statistically meaningful way and clindamycin.

Hill: To follow up on John Heffner's question, based on my experience with COPD patients' adherence during some of the noninvasive ventilation trials we've done, I've been impressed that, in comparison to your average asthma patient--and probably your average systemic hypertension patient as well--COPD patients often have many additional challenges. COPD patients are older; they tend to have less education; they often are from different cultures; they have co-morbidities; they have reimbursement issues, with limited Medicare coverage; they have. Tab. 2. Calculated physico-chemical parameters of the drugs tested. Partition coefficients [log P] Acrvedilol Propranolol Atenolol 3.29 2.80 0.56 Molar refractivity 115.79 76.82 73.5 Dipole moments [Debyes] 0.798 1.712 2.89 and clobetasol. MATERIALS AND METHODS Culture of Vascular Smooth Muscle Cells. Primary cultures of rat aortic vascular smooth muscle for use in the migration studies were prepared by an explant technique as described 18 ; . Cryopreserved primary cultures of human pulmonary artery smooth muscle cells passage 3 ; for use in the DNA synthesis studies were obtained from Clonetics San Diego ; . Cells were grown in a modified MCDB 131 formulation containing 5% fetal bovine serum, EGF at 10 ng ml, basic FGF at 2 ng ml, 1 dexamethasone, gentamicin sulfate at 10 , ug ml, and amphotericin B at 10 Clonetics ; . DNA Synthesis. Human vascular smooth muscle cells were plated into 24-well plates Corning ; 2 x 104 cells per cm2; passage 6 ; and grown to confluence 3 days ; . Cells were then made quiescent Go ; by substituting serum-containing medium with Dulbecco's modified Eagle's medium DMEM; GIBCO ; containing insulin 5 , ug ml ; , transferrin 5 pug ml ; , and sodium selenite 5 ng ml ; for 48 hr. Cells were replenished with fresh medium once between and after the 48-hr quiescent period. Carrvedilol was added 15 min prior to the addition of a mitogen for an additional 24-hr incubation. DNA synthesis was assessed by measuring the radioactivity incorporation 4 hr ; of [3H]thymidine into the trichloroacetic acid-insoluble fraction. Migration of Vascular Smooth Muscle. The procedure for assessing vascular smooth muscle cell migration has been described 19 ; . Briefly, rat aortic vascular smooth muscle cells passage 3 ; were suspended 1 x 106 cells per ml ; in serum-free DMEM supplemented with 0.2% bovine serum albumin Sigma ; . Migration assays were performed in modified Boyden chambers using Transwell Costar ; cell culture chambers with a polycarbonate pore size, 8 ; membrane. PDGF was dissolved in DMEM and placed in the lower compartment in the presence or absence of carvedilol. Vascular smooth muscle cells 5 x 10W cells ; were then loaded in the upper compartment and incubated for 24 hr at 37C in a humidified atmosphere containing 5% C02 95% air. Nonmigrated cells on the upper surface were scraped away gently and washed three times with phosphate-buffered saline. Filters were fixed in methanol and stained with Giemsa. The number of vascular smooth muscle cells per x 100 high-power field HPF ; that had migrated to the lower surface of the filters was determined microscopically. Four HPFs were counted per filter. Experiments were performed either in duplicate or in triplicate. Bafloon Angioplasty of Rat Carotid Arteries. The animals used in this study were divided into two groups: i ; those used for hemodynamic studies and ii ; those used for histopathologic examination of the degree of neointimal proliferation following carotid artery balloon angioplasty. These two major groups were further subdivided into animals that were treated with carvedilol 1 mg kg, i.p.; twice daily; %'5 ; umol kg-1.day-1 ; and those that served as controls which received an equal volume of carvedilol vehicle ; . All animals were pretreated with either carvedilol or vehicle 3 days prior to commencing either the hemodynamic studies or carotid artery angioplasty the latter group receiving carvedilol or vehicle for 14 days after surgery, at which time the animals were sacrificed for histological processing of the carotid arteries ; . Left common carotid artery balloon angioplasty was performed under aseptic conditions in anesthetized sodium pentobarbital, 65 mg kg, i.p. ; male Sprague-Dawley rats 380-420 g ; that had been pretreated for 3 days with either carvedilol or vehicle. After an anterior midline incision was. This drug must be used by obese people who have a bmi body mass index ; of 30 or above only, otherwise the side-effects will be there and clotrimazole. Packer m, et al : effect of carvedilol on survival in severe chronic heart failure.
1. Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada 2000. Ottawa, Canada, 1999. 2. No authors listed. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease LIPID ; Study Group. N Engl J Med 1998; 339: 1349-57. HPS Heart Protection Study Collaborative Group. MRC BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22. The Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure MERIT-HF ; Study Group. Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure MERITHF ; . Lancet 1999; 353: 2001-7. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001: 344; 1651-8. No authors listed. The Cardiac Insufficiency Bisoprolol Study II CIBIS-II ; : A randomised trial. Lancet 1999; 353: 9-13. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A metaanalysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-45. Fallen E, Cairns J, Dafoe W, et al. Management of the postmyocardial infarction patient: A consensus report revision of the 1991 CCS Guidelines. Can J Cardiol 1995; 11: 477-86. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC AHA guidelines for the ganagement of patients with acute myocardial and cutivate!

Assign treatment by container number. Commercial supplies of metoprolol tartrate and carvedilol were identically over-encapsulated, packaged, and labeled with unique container numbers. All participants and site sponsor personnel involved in conduct of the trial were blinded to treatment group. Each patient's dose was titrated progressively from 6.25 mg of carvedilol twice daily and 50 mg of metoprolol twice daily to a maximum dose of 25 mg and 200 mg twice daily, respectively, at 1- to 2-week intervals toward target BP levels for a total of 2 to weeks.10, 18 Target systolic BP was 135 mm Hg or less for those participants with baseline of 140 to 179 mm Hg and 130 mm Hg or less for those with baseline of 130 to 140 mm Hg. Target diastolic BP was 85 mm Hg less for those participants with baseline diastolic BP of 90 109 mm Hg and 80 mm Hg less for those participants with baseline diastolic BP of 80 Hg. A dose of 12.5-mg hydrochlorothiazide followed by a dihydropyridine calcium antagonist were added as necessary to achieve target BP. On reaching target BP or the highest dose level, participants began 5 months of maintenance therapy. Maximum study length per participant was 35 weeks, including down-titration as necessary and safety follow-up. No longer term follow-up was planned. 1 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study CONSENSUS ; . N Engl J Med 1987; 316: 142935. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293302. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 145056. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 134955. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II CIBIS-II ; : a randomised trial. Lancet 1999; 353: 913. MERIT-HF Study Group. Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure MERIT-HF ; . Lancet 1999; 353: 200107. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival COPERNICUS ; study. Circulation 2002; 106: 219499. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 70917. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the Study of Patients Intolerant of Converting Enzyme Inhibitors SPICE ; registry. Eur Heart J 1999; 20: 118290. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 112631. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397402. Swedberg K, Kster M, Rosn M, Schaufelberger M, Rosengren A. Decreasing one-year mortality from heart failure in Sweden: data from the Swedish Hospital Discharge Registry--1988 to 2000. J Coll Cardiol 2003; 41 suppl A ; : 190a abstr ; . Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and.
HANNA KRUSZEWSKA, TOMASZ ZAR BA and STEFAN TYSKI National Institute of Public Health, 30-34 Chemska Str., 00-725 Warsaw A variety of compounds which are involved in the management of diseases of non-infectious etiology have shown some antimicrobial activity in vitro, while testing against bacteria and other microorganisms 1-4 ; . Such compounds are called non-antibiotics. By the end of the nineteenth century the dyes were known to possess antimicrobial activity. Paul Ehrlich used methylene blue one of phenothiazines compounds as an antimicrobial agent 5 ; . So far, a lot of attention has been focused on phenothiazines which inhibit efflux pumps 6 ; , thioxanthenes and other agents with affinities to cellular transport systems 7-8 ; . The searches of non-antibiotics among drugs present on Polish pharmaceutical market have been performed in Drug Institute in Warsaw for last years. So far, about 500 drugs, randomly chosen from different groups of pharmaceutical products were examined. During these studies 9-11 ; , it was indicated that some of preparations inhibited growth of at least one of the examined strains. The drugs with the following active substances showed significant antimicrobial activity: acepromazine, butorphanol, cisapride, cisplatine, emadastine, fluvastatine, ketamine, levocabastine, matipranalol, methotrexate, nicergoline, perazine, proxymetacaine, sertraline, tegaserole, tetrahydrozoline, ticlopidine and tropicamide. The surveillance study was performed on standard microbial strains. The aim of this study was the continuation of searching and characterizing the antimicrobial activity expressed by selected non-antibiotic drugs, analyzed during state control performed in National Institute of Public Health in Warsaw. MATERIALS AND METHODS Materials The following microorganisms from American Type Culture Collection: Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538P, Candida albicans ATCC 10231 were used in the study. The following pharmaceutical products available on Polish market were randomly chosen for the analysis: Abutol 200 mg tabl. acebutolol ; , ACC 200 mg tabl. acetylocystein ; , Acecor 400 mg tabl. acebutolol ; , Aclotin 250 mg tabl. triclopidine ; , Acupro 40 mg tabl. quinapril ; , Advantan 0, 1% cream methylprednisolone ; , Aesculaforce 20 mg tabl. escin-Hippocastani semen ; , Agapurin 600 mg tabl. pentoxiphylline ; , Alergoftal 5 mg + 0, 5 mg ml antazoline, naphazoline ; , Amlopres 5 mg, 10 mg tabl., Amlovasc 5 mg tabl., Agen 10 mg tabl. amlodipine ; , Androgest 50 mg tabl. cyproterone ; , Antidiab 5 mg tabl. glipizide ; , Apo-Ranitidine 300 mg tabl. ranitidine ; , Arcoxia 60 mg tabl. etoricoxib ; , Baclofen 10 mg 25 mg tabl. baclofen ; , Balsolan 100 mg g ointment Balsamum peruvianum ; , Baycox 2.5% oral susp. toltrazuril ; , Bilberin 25% anthocyanosides caps. Betacoretum extractum ; , Bimanol 100 mg tabl. deanol ; , Bioaron C syrup extr.: Aloe arborescens, Aronia, ascorbic acid ; , Biosotal 80 mg tabl. sotalol ; , Bisoratio 10 mg tabl. bisoprolol ; , Byol 5 mg tabl. bisoprolol ; , Campral 333 mg tabl. acamprosatum ; , Cardiac drops Convallariae 50%, Cratagi 25%, Valerianae 25% ; , Cardiotnic Crategi tinct. 67 g + valerianae tint. 34 g 100 mL ; , Catalin 0, 75 mg 15 mL pirenoxine ; , Cavinton Forte 10 mg tabl. vinpocetine ; , Cecenu 40 mg caps. lomustin ; , Cetrize 10 mg tabl. cetirizini dihydrochloride ; , Cialis 20 mg tabl. tadalafil ; , Cicardin 2 mg tabl. melatonine ; , Cipramil 20 mg tabl., Citalopram 40 mg tabl. citalopram ; , Claritine 1 mg ml syrup loratadine ; , Clobederm 0, 05% ointment clobetasole ; , Codliver oil ointment oleum Jecoris Aselli ; , Concerta 18 mg tabl. methylfenidate ; , Coordinax 1 mg mL oral susp. cisapride ; , Coryol 12.5 mg tabl. carvedilol ; , Coxeton 500 mg tabl. nabumetone ; , Crixivan 100 mg caps. indinavir ; , Cuprenil 250 mg tabl. penicillamine ; , Curatoderm 0.00417 mg g ointment tocalcitol ; , Cyclo 3 forte Ruscus aculeatus ; , Cynara 400 solut. Cynarae scolymus ; , Debelizyna 100 g paste Phaseolus indiae ; , Dilzem retard 120 mg tabl. diltiazem ; , Dissenten 2 mg tabl. loperamide ; , Diuramid 250 mg tabl. acetozolamidum ; , Diuresin SR 1, 5 mg tabl. indapamide ; , Efectin 75 mg tabl. venlafaxine ; , Elocom 1mg g cream mometasone ; , Euclamin 5 mg tabl. glibenclamide ; , Euthyrox N 100 mg tabl. levothyroxine ; , Exacyl 500 mg tabl. tranexamic acid ; , Famvir 250 mg tabl. famciclovir ; , Feloten 10 mg tabl. felodipine ; , Fenactil 4% solution chlorpromazine ; , Fitoprost 160 mg caps. Serenoae repens fructus extr. ; , Flamexin 20 mg tabl. piroxicam ; , Flavobil 40 mg tabl. dry extr. Ginkgo biloba ; , Flexiderm 30% ointment sylibine ; , Forlax 400 mg powder 10 g macrogolum ; , Gabapentine 100 mg tabl. gabapentin ; , Gapten 1 mg tabl. trandiolapril ; , Gasec-20 and Gastrocaps 20 mg tabl. omeprazole ; , Gasprid 10 mg tabl. cisapride ; , Gastrografin 760 mg ml amidotrizoic acid ; , Geralen 20 mg caps. methoxsalen ; , Ginsengin 600 oral solution Ginseng radix ; , Ginsepan tabl. 15 mg ginsenosidesPapax ginseng ; , Glazide 80 mg tabl. gliclazide ; , Groprinosin 500 mg tabl. inosine pranobex ; , Guajazyl 20 mg g syrup gualfenesinum ; , Hascovir 200 mg tabl aciclovir ; , Heparinum 300 j.m. g heparine ; , Herbapect syrup extr.: Thymus vulgaris, Primula, sulfoguaiacol ; , Hydrochlorothiazidum 25 mg tabl. hydrochlorothiazide ; , Infacol 40 mg mL ; oral susp. simeticone ; , Isopto Carpine 20 mg tabl. pilocarpine ; , Izotziaja 0, 5% gel izotretinoine ; , Jacutin 3 mg g, emul.

Micromedex physicians desk reference data last updated 10 november 200 privacy policy november 200 privacy policy november 20 2006 medicinenet home page top 6 safety and veins to you and cilostazol.
Of the 5010 patients who underwent randomization, 2511 were assigned to receive valsartan and 2499 to receive placebo, all with background therapy for heart failure. There were no clinically relevant differences in the base-line characteristics of the two groups Table 1 ; . A description of the base-line demographic characteristics of this diverse population has been published previously.14 At the time of randomization, 93 percent of the patients were being treated with ACE inhibitors. The average daily doses were 17 mg of enalapril, 19 mg of lisinopril, 80 mg of captopril, 6 mg of ramipril, and 23 mg of quinapril. Thirty-five percent of the patients were receiving beta-blockers 15 percent were receiving carvedilol, 12 percent metoprolol, and 3 percent atenolol ; , and randomization was stratified according to their use or nonuse; this percentage remained stable throughout the study. Only 5 percent of the patients were treated with spironolactone. The overall mean duration of followup was 23 months range, 0 to 38 ; . The target dose was achieved in 84 percent of the patients receiving valsartan mean dose, 254 mg ; and 93 percent of those receiving placebo mean equivalent dose, 283 mg ; . Systolic blood pressure was reduced to a greater extent with valsartan than placebo: at four months, it was reduced by a mean SD ; of 5.215.8 mm Hg in the valsartan group, as compared with 1.214.8 mm Hg in the placebo group, and at one year the reductions were 5.216.0 mm Hg and 1.315.9 mm Hg, respectively. The mean heart rate was unchanged.
In the present study, carvedilol at relatively high doses attenuated the increase in LVEDD and LVESD and, at the highest dose, attenuated the decrease in LVEF in rats with coronary stenosis, whereas it did not attenuate them at any dose in rats with permanent coronary occlusion. In contrast, propranolol and metoprolol at doses showing similar effects as carvedilol on lowering HR and SBP in the resting state did not decrease LVESD and did not increase LVEF in rats with coronary stenosis, but they attenuated or tended to attenuate the increase in LVEDD. The SBP-lowering effect of bunazosin was similar to that of blockade, but this blockade failed to attenuate LV dysfunction and remodeling. As far as we know, this is the first study to show that carvedilol preferentially attenuates LV remodeling and dysfunction induced by coronary stenosis rather than by coronary occlusion. These results suggest that the effect of -blockers on myocardial ischemia and ischemia-related abnormalities might depend on the -blockers used and the doses applied and that the presence of compromised ischemic but viable myocardium seems to be necessary for cardioprotection by a blocker. In the C10 and C30 stenosis groups, modulation of LV function and morphology is likely to be associated intimately with an increase in MBF and CFR. Because the coronary stenosis severity was similar among the 9 treatment groups examined and HR and LVSP, determinants of cardiac work, were not increased in both groups, the increases in MBF and CFR seem to be attributable to improvement of coronary microvascular dilating function. In addition, from the results with bunazosin, a significant contribution of a blockade to the effect on the C10 and C30 stenosis groups is unlikely. AFR was lower and vitamin C was higher in the C30 but not in the C2 stenosis group than in the V stenosis group. The level of AFR reflects the sum of radicals trapped by endogenous vitamin C, suggesting that the C30 treatment reduced oxygen radicals, thereby sparing the consumption of endogenous antioxidant. Thus, the antioxidant activity of carvedilol may have contributed.
And or hypotension. In order to minimize the occurrence of orthostatic effects, carvedilol should be taken with food.7, 46, 47 Excessive hypotension or syncope and signs or symptoms of vasodilatation can be treated by reducing the dose of diuretics or ACE inhibitors. Transient worsening of heart failure peripheral edema, weight gain, shortness of breath ; often responds to increased dosages of diuretics or ACE inhibitor. If the problem persists, the dose of carvedilol may need to be decreased or discontinued. Patients receiving carvedilol who are hospitalized for exacerbation of heart failure and or cardiogenic shock should not receive carvedilol until the condition is stabilized.50, 52. 1. Bristoww MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Resp 1978; 62: 873-879. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Eng J Med 1991; 324: 808-815. CIBIS Investigators and committees: A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study CIBIS ; . Circulation 1994; 90: 1765-1773. Packer M, Bristow MR, Cohen JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996; 334: 1349-1355. Shaddy RE, Oslen SL, Bristow MR, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Heart J 1995; 129: 197- Frishman WH. Alpha-and beta-adrenergic blocking drugs. IN: Frishman WH, Sonnenblick EH, Eds. Cardiovascular Pharmaco-therapeutics. New York: McGraw-Hill 1997; p 59-94. Sackner-Bernestein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA1995; 274: 1462-1467.

ADVISORY BOARD What guides the selection of the -blockers used in a patient with CHF? VAN BAKEL Whether the beneficial impact of -blockers represents, as we think with ACE inhibitors, a class effect is still unclear. Based on clinical trials within the -blocker class, we know that carvedilol, sustained-release metoprolol, and bisoprolol work and that nonsustained-release metoprolol has produced equivocal results in terms of survival. Part of the controversy stems from a recent clinical study called BEST -blocker Evaluation Survival Trial ; , in which the nonselective -blocker bucindolol produced mixed results. What is interesting about this study was that, on subgroup analysis, white NYHA class III CHF patients did well but African American NYHA class III patients did poorly. In addition, NYHA class IV CHF patients in both of these groups did poorly. When the data were combined, there was a neutral effect. At least partially as a result of this study, the issue of race differences and the efficacy of these different drugs is just now coming onto the forefront. ADVISORY BOARD You discussed the importance of titrating up the dose of ACE inhibitors in patients with advanced CHF to the equivalent doses used in clinical trials as tolerated. What are the blood pressure parameters below which you get uncomfortable even if the patient denies any symptoms? VAN BAKEL The numbers depend on the etiology of the patient's underlying disease. In an outpatient with dilated cardiomyopathy and normal coronary arteries, I think a systolic pressure of 80 mm.

TABLE 1. Continued Special indications Skin preparation Surgical preparation Skin preparation Additional considerations Immediate onset, but no residual activity Intermediate onset, but prolonged residual action Inactivated by blood or serum proteins Resistance N A N Documented in P. aeruginosa, but stable.

Carvedilol tablets ; : - non-selective beta-adrenoceptor blocker, blocks alpha-receptors and has anti-oxidant activity.